Score Overview
Explore the 2021 public Archive ranking →
Where Nektar Therapeutics has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- NKTR
2005: 85.3% · 2021: 96.1% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 60.40 | — |
1 Year2025-09-26 | $ 58.50 | 3.25% |
5 Years2021-09-28 | $ 276.30 | -78.14% |
10 Years2016-09-28 | $ 265.05 | -77.21% |
20 Years2006-09-28 | $ 214.35 | -71.82% |
30 Years1996-09-27 | $ 97.50 | -38.05% |
All Time1994-05-03 | $ 56.25 | 7.38% |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1994-05-03 |
|---|---|---|---|---|---|---|---|
| Price | $ 60.40 | $ 58.50 | $ 276.30 | $ 265.05 | $ 214.35 | $ 97.50 | $ 56.25 |
| Return | — | 3.25% | -78.14% | -77.21% | -71.82% | -38.05% | 7.38% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 55M | -$ 158M | $ 568M |
| 2025 | $ 55M | -$ 164M | $ 245M |
| 2024 | $ 98M | -$ 118M | $ 255M |
| 2023 | $ 90M | -$ 276M | $ 303M |
| 2022 | $ 92M | -$ 368M | $ 504M |
| 2021 | $ 101M | -$ 523M | $ 733M |
| 2020 | $ 152M | -$ 444M | $ 1.06B |
| 2019 | $ 114M | -$ 440M | $ 1.32B |
| 2018 | $ 1.19B | $ 681M | $ 1.33B |
| 2017 | $ 307M | -$ 96M | $ 296M |
| 2016 | $ 165M | -$ 153M | $ 389M |
| 2015 | $ 230M | -$ 81M | $ 308M |
| 2014 | $ 200M | -$ 53M | $ 237M |
| 2013 | $ 148M | -$ 162M | $ 237M |
| 2012 | $ 81M | -$ 171M | $ 277M |
| 2011 | $ 71M | -$ 133M | $ 241M |
| 2010 | $ 159M | -$ 37M | $ 315M |
| 2009 | $ 71M | -$ 102M | $ 396M |
| 2008 | $ 90M | -$ 34M | $ 378M |
| 2007 | $ 273M | -$ 32M | $ 482M |
| 2006 | $ 217M | -$ 154M | $ 458M |
| 2005 | $ 126M | -$ 185M | $ 476M |
| 2004 | $ 114M | -$ 101M | $ 418M |
| 2003 | $ 106M | -$ 46M | $ 285M |
| 2002 | $ 94M | -$ 107M | $ 293M |
| 2001 | $ 77M | -$ 250M | $ 344M |
| 2000 | $ 51M | -$ 97M | $ 484M |
| 1999 | $ 41M | -$ 38M | $ 138M |
| 1998 | $ 21M | -$ 18M | $ 82M |
| 1997 | $ 16M | -$ 9M | $ 100M |
| 1996 | $ 6M | -$ 10M | $ 18M |
| 1995 | $ 3M | -$ 7M | $ 3M |
| IPO1994 | $ 1M | -$ 5M | $ 10M |
Nektar Therapeutics fundamental performance
Between 2020 and 2025, revenue declined from $ 152M to $ 55M and net income went from -$ 444M to -$ 164M. Revenue increased in 2 of those 5 years; net income in 4.
Between 2015 and 2025, revenue declined from $ 230M to $ 55M and net income went from -$ 81M to -$ 164M. Revenue increased in 5 of those 10 years; net income in 6.
Nektar Therapeutics currently holds a 20-year HDB Score of 2.6 out of 10. How the HDB Score is calculated.
Membership
Continue NKTR’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
